Compare Motorola Solutions Inc (MSI) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Motorola Solutions (MSI) trades at $462.98, down 1.08% today, with strong technical support at $459 and bullish moving averages. The company shows robust fundamentals with Q2 2026 EPS beating expectations at $4.41 vs. $3.85, revenue growth to $11.68B in 2025, and a $2B share repurchase authorization announced September 2026. Recent acquisition of D-Fend Solutions for $1.5B expands counter-drone capabilities.

Outlook remains positive with 70.6% analyst buy ratings and $536.50 consensus price target, representing 16% upside. Risks include elevated valuation multiples (P/E 36.48) and significant capital expenditures driving negative cash flow. The stock offers growth potential through security technology expansion but faces execution risks from recent acquisitions and competitive pressures.

Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.

Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.